Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 13.62
KMDA's Cash-to-Debt is ranked lower than
55% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. KMDA: 13.62 )
Ranked among companies with meaningful Cash-to-Debt only.
KMDA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.65  Med: 4.49 Max: 90.83
Current: 13.62
0.65
90.83
Equity-to-Asset 0.68
KMDA's Equity-to-Asset is ranked higher than
52% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. KMDA: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
KMDA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.66 Max: 0.73
Current: 0.68
0.28
0.73
Debt-to-Equity 0.03
KMDA's Debt-to-Equity is ranked higher than
85% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. KMDA: 0.03 )
Ranked among companies with meaningful Debt-to-Equity only.
KMDA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.18 Max: 1.61
Current: 0.03
0
1.61
Debt-to-EBITDA 0.99
KMDA's Debt-to-EBITDA is ranked higher than
70% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. KMDA: 0.99 )
Ranked among companies with meaningful Debt-to-EBITDA only.
KMDA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.15  Med: -0.9 Max: 7.71
Current: 0.99
-3.15
7.71
Piotroski F-Score: 5
Altman Z-Score: 3.53
Beneish M-Score: -0.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1.82
KMDA's Operating Margin % is ranked higher than
70% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. KMDA: -1.82 )
Ranked among companies with meaningful Operating Margin % only.
KMDA' s Operating Margin % Range Over the Past 10 Years
Min: -121.42  Med: -16.25 Max: 5.83
Current: -1.82
-121.42
5.83
Net Margin % -2.24
KMDA's Net Margin % is ranked higher than
69% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. KMDA: -2.24 )
Ranked among companies with meaningful Net Margin % only.
KMDA' s Net Margin % Range Over the Past 10 Years
Min: -170.4  Med: -17.36 Max: 0.63
Current: -2.24
-170.4
0.63
ROE % -2.92
KMDA's ROE % is ranked higher than
74% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. KMDA: -2.92 )
Ranked among companies with meaningful ROE % only.
KMDA' s ROE % Range Over the Past 10 Years
Min: -196.88  Med: -15.11 Max: 1.02
Current: -2.92
-196.88
1.02
ROA % -2.02
KMDA's ROA % is ranked higher than
75% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. KMDA: -2.02 )
Ranked among companies with meaningful ROA % only.
KMDA' s ROA % Range Over the Past 10 Years
Min: -59.18  Med: -10.19 Max: 0.39
Current: -2.02
-59.18
0.39
ROC (Joel Greenblatt) % -3.41
KMDA's ROC (Joel Greenblatt) % is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. KMDA: -3.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KMDA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -179.58  Med: -22.1 Max: 15.92
Current: -3.41
-179.58
15.92
3-Year Revenue Growth Rate -0.70
KMDA's 3-Year Revenue Growth Rate is ranked lower than
57% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. KMDA: -0.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KMDA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.7  Med: 4.6 Max: 50.5
Current: -0.7
-8.7
50.5
GuruFocus has detected 3 Warning Signs with Kamada Ltd KMDA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KMDA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

KMDA Guru Trades in Q3 2016

Jim Simons 188,500 sh (+9.09%)
John Paulson 730,800 sh (-0.72%)
» More
Q4 2016

KMDA Guru Trades in Q4 2016

Jim Simons 227,000 sh (+20.42%)
John Paulson 730,800 sh (unchged)
» More
Q1 2017

KMDA Guru Trades in Q1 2017

Jim Simons 264,800 sh (+16.65%)
John Paulson 730,800 sh (unchged)
» More
Q2 2017

KMDA Guru Trades in Q2 2017

Jim Simons 342,200 sh (+29.23%)
John Paulson 790,800 sh (+8.21%)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Add 8.21%$5.93 - $8.25 $ 5.10-28%790,800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ROCO:6492, NAS:MACK, TSX:ZYME, NAS:MNKD, LSE:VRP, TSE:2395, TPE:1720, NAS:CGEN, NAS:VTVT, OSTO:MVIR B, NAS:SBPH, XKRX:005690, LSE:TRX, NAS:CASC, OTCPK:COCP, NAS:VTL, NAS:OCUL, NAS:ALRN, ROCO:6617, BOM:531349 » details
Traded in other countries:K3M.Germany, KMDA.Israel,
Headquarter Location:Israel
Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops & produces specialty plasma-derived protein therapeutics. Its flagship product include Glassia.

Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.

Ratios

vs
industry
vs
history
PB Ratio 2.64
KMDA's PB Ratio is ranked higher than
70% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KMDA: 2.64 )
Ranked among companies with meaningful PB Ratio only.
KMDA' s PB Ratio Range Over the Past 10 Years
Min: 1.62  Med: 3.13 Max: 13.7
Current: 2.64
1.62
13.7
PS Ratio 2.14
KMDA's PS Ratio is ranked higher than
87% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. KMDA: 2.14 )
Ranked among companies with meaningful PS Ratio only.
KMDA' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.25 Max: 16.84
Current: 2.14
1.89
16.84
Price-to-Operating-Cash-Flow 104.93
KMDA's Price-to-Operating-Cash-Flow is ranked lower than
89% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. KMDA: 104.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
KMDA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 94.21  Med: 127.53 Max: 182.4
Current: 104.93
94.21
182.4
EV-to-EBIT -111.78
KMDA's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. KMDA: -111.78 )
Ranked among companies with meaningful EV-to-EBIT only.
KMDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -177.5  Med: -12.4 Max: 1579
Current: -111.78
-177.5
1579
EV-to-EBITDA 86.99
KMDA's EV-to-EBITDA is ranked lower than
89% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. KMDA: 86.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
KMDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -363  Med: -13.2 Max: 183.8
Current: 86.99
-363
183.8
EV-to-Revenue 1.97
KMDA's EV-to-Revenue is ranked higher than
90% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. KMDA: 1.97 )
Ranked among companies with meaningful EV-to-Revenue only.
KMDA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 2.8 Max: 16.8
Current: 1.97
1
16.8
Current Ratio 2.85
KMDA's Current Ratio is ranked lower than
63% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KMDA: 2.85 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.18 Max: 4.92
Current: 2.85
2.21
4.92
Quick Ratio 1.95
KMDA's Quick Ratio is ranked lower than
71% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. KMDA: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.29 Max: 4.02
Current: 1.95
1.45
4.02
Days Inventory 156.15
KMDA's Days Inventory is ranked lower than
58% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. KMDA: 156.15 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 97.6  Med: 154.27 Max: 175.19
Current: 156.15
97.6
175.19
Days Sales Outstanding 103.34
KMDA's Days Sales Outstanding is ranked lower than
74% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. KMDA: 103.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.76  Med: 93.2 Max: 131.52
Current: 103.34
45.76
131.52
Days Payable 121.95
KMDA's Days Payable is ranked higher than
74% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. KMDA: 121.95 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 113.28 Max: 174.99
Current: 121.95
89.24
174.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
KMDA's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. KMDA: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KMDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33.2  Med: -9.3 Max: -0.5
Current: -0.5
-33.2
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 4.08
KMDA's Price-to-Net-Current-Asset-Value is ranked higher than
72% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. KMDA: 4.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KMDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.54  Med: 4.98 Max: 44.49
Current: 4.08
2.54
44.49
Price-to-Tangible-Book 2.63
KMDA's Price-to-Tangible-Book is ranked higher than
76% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. KMDA: 2.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KMDA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.43  Med: 3.24 Max: 12.43
Current: 2.63
1.43
12.43
Price-to-Median-PS-Value 0.66
KMDA's Price-to-Median-PS-Value is ranked higher than
72% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. KMDA: 0.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KMDA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 0.94 Max: 5.15
Current: 0.66
0.62
5.15
Earnings Yield (Greenblatt) % -0.90
KMDA's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. KMDA: -0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KMDA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.6  Med: -1.7 Max: 2.3
Current: -0.9
-14.6
2.3

More Statistics

Revenue (TTM) (Mil) $87.83
EPS (TTM) $ -0.05
Beta1.09
Short Percentage of Float0.50%
52-Week Range $3.75 - 8.61
Shares Outstanding (Mil)40.25

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 103 136 196 228
EPS ($) 0.04 0.22 0.65 0.90
EPS without NRI ($) 0.04 0.22 0.65 0.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}